clinical trial · NCT07668336
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company·phase3·not yet recruiting·n = 170
Diabetes Mellitus, Type 2OrforglipronDulaglutide
brief summary
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.
started
Sep 1, 2026
primary completion
Mar 1, 2030
completion
Mar 1, 2030
last updated
Jul 20, 2026
official title
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol